SAREPTA THERAPEUTICS, INC. financials

SRPT CIK 0000873303

Source: EDGAR filings · Built 2026-06-02T04:05:43Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -307.45M -342.74M -577.10M -356.17M -481.66M 25.26M
EBITDA -655.26M 255.81M -223.43M -494.34M -421.69M -537.25M
Working Capital 1.44B 2.34B 1.93B 1.94B 2.15B 2.07B
Net Debt 238.27M 239.86M 968.38M 650.58M -1.50B -1.40B
Gross Margin -1.56% 28.29%
Operating Margin -37.54% 12.20% -23.39% -63.55% -75.07% -123.76%
Net Margin -38.27% 13.16% -46.82% -83.37% -68.38% -121.56%
Return on Equity (ROE) -62.55% 15.40% -62.37% -182.75% -45.13% -72.74%
Return on Assets (ROA) -21.30% 5.94% -16.42% -22.49% -13.30% -18.57%
Current Ratio 2.32× 4.20× 3.95× 4.13× 5.75× 5.97×
Debt-to-Equity 0.91× 0.88× 1.63× 4.20× 0.67× 0.13×
Effective Tax Rate -1.59% 9.79% -3.05% -1.96% 0.04% -0.19%
Cash Conversion Ratio 0.29× -0.87× 0.93× 0.46× 1.06× -0.19×
Accruals Ratio -0.15× 0.11× -0.01× -0.12× 0.01× -0.22×
SBC % of Revenue 6.62% 10.31% 15.94% 27.62% 18.61% 23.71%
CapEx Coverage -2.02× -1.50× -6.58× -10.55× -11.51× 1.31×
Free Cash Flow Per Share $-3.07 $-3.18 $-6.25 $-4.07 $-5.93 $0.32

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 51.96×
P/FCF 526.04×
FCF Yield 0.19%
EV / EBITDA 47.00×
P/S 1.21× 6.59× 7.89× 13.51× 12.81× 29.69×
P/B 1.98× 7.71× 10.52× 29.61× 8.45× 17.76×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.86B 1.79B 1.14B 843.77M 612.40M 455.87M
Revenues 2.20B 1.90B 1.24B 933.01M 701.89M 540.10M
Cost of Revenue 25.50M
Gross Profit -29.10M 505.85M
Research and Development Expense 207.24M
Selling, General and Administrative Expense 491.72M 557.87M 481.87M 451.42M 282.66M 317.88M
Operating Income (Loss) -699.78M 218.08M -267.82M -536.20M -459.71M -564.16M
Income Tax Expense (Benefit) 11.19M 25.54M 15.88M 13.53M -168.00K 1.06M
Net Income (Loss) Attributable to Parent -713.41M 235.24M -535.98M -703.49M -418.78M -554.13M
Earnings Per Share, Basic $-7.13 $2.47 $-5.80 $-8.03 $-5.15 $-7.11
Weighted Average Number of Shares Outstanding, Basic 100.12M 95.08M 92.40M 87.56M 81.26M 77.96M
Earnings Per Share, Diluted $-7.13 $2.34 $-5.80 $-8.03 $-5.15 $-7.11
Weighted Average Number of Shares Outstanding, Diluted 100.12M 107.88M 92.40M 87.56M 81.26M 77.96M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 801.28M 1.10B 428.43M 966.78M 2.12B 1.50B
Assets, Current 2.54B 3.07B 2.58B 2.56B 2.60B 2.49B
Assets 3.35B 3.96B 3.26B 3.13B 3.15B 2.98B
Long-term Debt 828.97M 1.14B 1.24B 1.54B 563.67M
Liabilities, Current 1.10B 731.68M 653.66M 619.60M 452.73M 416.03M
Liabilities 2.21B 2.44B 2.41B 2.74B 2.22B 2.22B
Stockholders' Equity Attributable to Parent 1.14B 1.53B 859.34M 384.95M 928.01M 761.76M
Common Stock, Shares, Outstanding 104.96M 96.90M 93.73M 87.95M 87.13M 79.37M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -205.48M -205.79M -500.99M -325.35M -443.17M 107.47M
Payments to Acquire Property, Plant, and Equipment 101.97M 136.96M 76.11M 30.82M 38.49M 82.20M
Net Cash Provided by (Used in) Investing Activities 69.64M 755.56M -165.80M -1.05B 495.41M -121.72M
Payments for Repurchase of Common Stock 25.01M 0 0
Net Cash Provided by (Used in) Financing Activities -168.34M 124.81M 125.00M 232.51M 561.57M 682.32M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (SRPT CIK 0000873303), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

HCA

HCA Healthcare, Inc.

RC

READY CAPITAL CORPORATION

ASMB

ASSEMBLY BIOSCIENCES, INC.